Within the Central Nervous System (CNS), Bone Marrow derived Mesenchymal Stem Cells (BM-MSC) may promote activation of helper cells (microglia and macrophages), rescue neurons from programed cell death (apoptosis) and sometimes induce nerve growth (trophic effects).
This is exciting news for patients who suffer from ALS, spinal cord injury and stroke.
See below for disease-specific details.
Stroke is a major health problem in society affecting millions per year. There are both animal and human studies that suggest that bone marrow mesenchymal stem cell transplantation can safely offer neuro-restorative therapy for stroke victims. In particular, intravenous administration of autologous MSCs has been shown to reduce the size of a stroke in the brain by greater than 20% when delivered between 36 to 133 days after the stroke (Honmou, et al 2011). Even studies done last year show some promising results of transplanting bone marrow derived MSCs for stroke (Bhasin, et al, 2013) (Steinberg, 2016).
So for stroke, Cedar Stem Cell Insitute in Columbus, Ohio can offer IV administration of bone marrow derived stem cells from a patients own hip (iliac crest) as an outpatient procedure.
Stem cell and PRP treatments for Multiple Sclerosis
The unmet need for therapies capable of repairing the central nervous system (CNS) damage occurring in many diseases including multiple sclerosis (MS) has sparked the interest of the neurological community for stem cell-based therapies. Unfortunately more than half of patients with multiple sclerosis have progressive disease characterized by accumulation disability. An exhaustive amount of animal data has shown that the intravenous administration of mesenchymal stem cells (MSC), effectively ameliorates experimental autoimmune encephalomyelitis (EAE), a model of MS, through the release of anti-inflammatory and neuroprotective molecules. There is growing medical evidence that Stem cell transplantation including mesenchymal cells can help treat autoimmune diseases such as Multiple Sclerosis in people (Tyndall, et al, 2016). In a large study of over 2000 patients using hematopoietic stem cell transplantation for severe autoimmune diseases, around 30% of these patients had a complete response (Tyndall, et al, 2016). Dr. Peter Connick’s group in Cambridge, England in 2012 report some clinical success using iv administration of autologous mesenchymal stem cells (from your own bone marrow) in patients with MS. They recording some improvements in vision. This was published in the most prestigious medical journal called Lancet Neurology. Dr. Burman and team in Sweden in 2014 also reported success with autologous hematopoietic stem cell transplantation (HSCT) for treating aggressive MS. At 5 years, relapse free survival was 87%, and MRI event-free survival 85%. HSCT is very effective treatment and can be performed with a high degree of safety. Dr. Burman also more recently in 2018, wrote a review article summarizing the successes of autologous HSCT for various neurological diseases. Dr. Yamout et al in 2010 showed improvement of vision and decreased disability scores in patients with MS after intrathecal (spinal tap) injection of bone marrow mesenchymal stem cells.
Lyme gets its name from place first diagnosed, Old Lyme, Connecticut 1975. Lyme disease is caused by bacterial infection by Borrelia burgdorferi transmitted by Dear Tick bite
The tick has to lock onto your skin for at least 36 hrs. to transmit the bacteria to you. Ticks pick up the bacteria from the Dear or Mice that they bite. Then bacteria is transmitted to humans. 300,000 cases per year in US and 65,000 per year in Europe. Tick bites give a skin rash, sometimes looks like Bull’s Eye target. However, 25% have no rash. Patients get flu like symptoms, such as fever, headache and fatigue but resolves. May get Bell’s palsy, or palpitations, or shooting pain in arms or legs.
When symptoms linger well beyond the typical treatment time, you may have what's called "post-treatment Lyme disease syndrome" (PTLDS). It’s also called "chronic Lyme disease."
About 10-20% people who get Lyme disease have lingering symptoms greater than 6 months. A wide range of effects from PTLDS can go on for months. Some call Lyme disease "the great imitator" because its symptoms tend to mimic many other problems. Fatigue , muscle aches and headaches similar to fibromyalgia or chronic fatigue syndrome.
Sometimes Depression sets in secondary to having stress and having to cope with these symptoms for so long.
50% of patients get Arthritis and joint pain. Headaches sometimes associated with short term memory loss or thinking problems Numbness or tingling in face, arms, hands or legs.
Conventional medical treatment consists of Remove entire tick with tweezers and Antibiotic for 2-4 weeks, usually doxycycline.
Sometimes holistic remedies like Dr. Horowitz protocols. Dr. Horowitz protocols consist of various anti-inflammatory and detoxing. He calls it “turn off the faucet and shut down the production of inflammatory molecules, and open up the drain, improving the functioning of the detoxification pathways of the body, to get rid of the toxins.” This can usually be accomplished using medications that control inflammation like low dose naltrexone (LDN), but also using natural approaches like a trial of giving up gluten and grains, avoiding allergic foods and nightshades (potatoes, tomatoes, eggplant and peppers), or doing an alkaline diet with lots of healthy fruits and vegetables, while using phytochemical supplements that also turn on anti-inflammatory genes in the body. Tumeric (curcurmin), green tea extract (EGCG), resveratrol (the red wine/grape extract), and broccoli seed extract (sulforaphane), combined with omega 3 fatty acids, can all help lower inflammation. We also have had success decreasing Herxheimer reactions by alkalizing (drinking lemons and limes in water or taking Alka Seltzer Gold) while taking liposomal glutathione and/or clay/charcoal, which helps remove toxins from the body. If you do all this while properly detoxifying, it helps the majority of patients.
At Cedar we offer using your own PRP and your own autologous bone marrow aspirate concentrate (BMAC) that we harvest from your hip. These treatments help your immune system repair damages from the bacteria. We offer both intravenous or intrathecal (spinal tap) injection routes. Very safe treatment, but Not FDA approved.
Please contact our office to learn more.
Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis (ALS)—also known as "Lou Gehrig's Disease"—is a rare, neurodegenerative disorder leading to the loss of motor neurons ultimately leading to death. After diagnosis, the average lifespan ranges from 3 to 5 years, and death usually results from respiratory failure. Although the pathogenesis of ALS remains unclear, multiple factors are thought to contribute to the progression of ALS, such as network interactions between genes, environmental exposure, impair molecular pathways and many others. The neuroprotective properties of neural stem cells (NSCs) and the paracrine signaling of mesenchymal stem cells (MSCs) have been examined in multiple studies of ALS with promising results. The data from these initial trials indicate a reduction in the rate of disease progression.
Stem cell therapy is now available for patients with Autism or Autism Spectrum Disorder (ASD) and report a relatively high success rate of meaningful neurological improvement (Sharma, et al 2013, Sharma, et al 2012). One study of several patients showed about 88% incidence of neurological improvement after intrathecal injection of mesenchymal stem cells (Sharma, 2012). Here at Phenicell Regenerative Institute, we offer treatment options for autism, including intrathecal mesenchymal stem cell therapy with and without Platelet-Rich Plasma (PRP). In 2019 Riordan et al studied intravenous human umbilical cord blood (36 million cells once every 3 months) was helpful in children with Autism spectrum disorder. They studied 20 children ages 6-16 years old. They used the Autism Treatment Evaluation Checklist (ATEC) and the Childhood Autism Rating Scale (CARS) as measuring tools."
Intrathecal Bone Marrow Aspirate Concentration (BMAC) that we use at Cedar SCI has been used successfully by other doctors as well to treat Parkinson's Disease (Zakerinia, 2018). The Zakerinia group studied 220 patients with a variety of neurological conditions including 12 patients with Parkinson's Disease From 2011 to 2018. Theses patients received intrathecal BMAC and 9 of the 12 (75%) showed substantial neurological improvement.
Stem Cells and Exosomes Treatment for Alzheimer’s Disease
Alzheimer’s Disease (AD) as a dementia and neurodegenerative disease is mostly prevalent among people over 65 years of age. Approximately 50 million people live with dementia worldwide. Arguably, AD represents the most significant medical, social, and economic crisis of our time. Due to inefficiency of traditional pharmacological treatments and the lack of a long term cure, a strong interest in stem cell therapies have emerged and have provided promising results in experimental models and in some clinical trials (Duncan, et al, 2017). In addition to stem cell therapy more recent research supports the injection of targeted exosomes to treat Alzheimer’s disease (Yin et al, 2020). Here at Phenicell Regenerative Institute, we offer both intravenous mesenchymal adult stem cells treatment from umbilical cord blood as well as intravenous exosome therapy. Please contact us at Cedar SCI for more information.
Idiopathic Cerebellar Ataxia
Stem cell-based and regenerative therapy may become a hopeful treatment for neurodegenerative diseases including cerebellar degenerations. Neurotransplantation therapy mainly aims to substitute lost cells, but potential effects might include various mechanisms including nonspecific trophic effects and stimulation of endogenous regenerative processes and neural plasticity. Here at Phenicell, we have experience treating cerebellar ataxia with iv stem cells and iv exosomes with some success in post treatment speech, swallowing and improvement in motor skills. Exosomes are nanoparticles of genetic material which are thought to cross the blood brain barrier. Contact our office for more information.
Mitoma H, Manto M, Gandini J. Recent Advances in the Treatment of Cerebellar Disorders. Brain Sci. 2019 Dec 23;10(1):11.
Cendelin, J: Transplantation and Stem Cell Therapy for Cerebellar Degenerations. Cerebellum 2016 Feb;15(1):48-50.